Bristol-Myers Squibb, a pharmaceutical company headquartered in New York City, received from the U.S. Food and Drug Administration Orphan Drug Designation for its investigational antibody, anti-eTau (BMS-986168) for the treatment of Progressive Supranuclear Palsy (PSP). PSP is a rare brain disorder characterized by progressive problems with control of gait, balance, complex eye movement and mood abnormalities. The cause of this disorder is unknown and there is currently no effective treatment for PSP. BMS-986168 is a preclinical monoclonal antibody against Tau protein, which binds the cell’s internal skeleton and may help regulate the activity of brain cells. Under pathological conditions, tau can form abnormal deposits called neurofibrillary tangles, which can disrupt the activities of brain cells and lead to diseases. PSP is one form of Tau dysfunction condition with abnormal accumulation of tau as its pathological hallmark. Currently, Bristol-Myers Squibb is sponsoring a phase I clinical trial to evaluate safety and pharmacokinetic/pharmacodynamic profile for this investigational antibody.